Elevated Level of miR‐551b‐5p is Associated With Inflammation and Disease Progression in Patients With Severe Acute Pancreatitis

Abstract

Circulating microRNAs have the potential to be noninvasive biomarkers for assessing disease progression. MicroRNA-551b-5p (miR-551b-5p) was previously reported to be differentially expressed in pancreatic patients. The serum miR-551b-5p level was measured in patients with mild acute pancreatitis (MAP), severe acute pancreatitis (SAP), and healthy controls using quantitative real-time polymerase chain reaction (RT-PCR) analysis to evaluate its impact on inflammatory response. Acute Physiology and Chronic Health Evaluation II (APACHE II), Multiple Organ Dysfunction Score (MODS), Sequential Organ Assessment Score (SOFA), and Ranson's scores were recorded. Inflammatory cytokines, IL-6, IL-17, IL-1β, and Tumor Necrosis Factor-α (TNF-α), were detected in serum samples obtained from MAP and SAP patients on admission day 1, day 3, and day 5 using Enzyme Linked Immunosorbent Assay (ELISA). Inflammatory cytokines were analyzed in peripheral blood mononuclear cells (PBMCs), which were transfected with miR-551b-5p-negative controls and inhibitors. The serum miR-551b-5p level was significantly higher in MAP and SAP patients compared to controls (P < 0.001). An elevated miR-551b-5p level is positively associated with APACHE II, MODS, SOFA, and Ranson's scores (P < 0.001). Serum cytokines levels were significantly elevated in MAP and SAP patients compared to controls (P < 0.05). In addition, the level of these inflammatory cytokines was increased in PBMCs of SAP patients in comparison with those of healthy controls (P < 0.05), and this rise was significantly reduced with the addition of an miR-551b-5p inhibitor. In conclusion, serum miR-551b-5p is elevated in patients with MAP and SAP and is involved in the regulation of inflammatory response. It may be a useful biomarker for assessing the severity of SAP.

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

“…These results encourage future studies on the potential role of MALAT1 in CCA. In addition, increased levels of miR-604 and miR-551B in serum EVs from patients with CCA also provided excellent diagnostic capacities (up to 0.944) for CCA and some studies already started to evaluate their involvement in carcinogenesis and as diagnostic biomarkers [87][88][89][90]. Considering the high resistance of small ncRNAs to RNase degradation, additional efforts should be employed in order to validate their diagnostic accuracy.…”

MicroRNAs in acute pancreatitis: From pathogenesis to novel diagnosis and therapy

“…For example, cecum injury sometimes leads to serum amylase and lipase elevation but cannot bother the concentration of miR‐216a in circulation (Kong et al, ). More important, a quite number of research works suggest that there is a good correlation between serum miRNA and severity of AP (Blenkiron et al, ; M. Gao et al, ; Liu et al, ; P. Lu et al, ; Y. Zhang et al, ), and that some miRNAs can reflect the degree of injury to some extent (Calvano et al, ; Wang et al, ) and assist the diagnosis of AP‐associated ALI (X. G. Lu et al, ; N. Shi et al, ). Taken together, the superiority of miRNAs indicates that they have potential as a reference for predicting disease outcomes and guiding treatment.…”

Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in�vitro analysis

“…Plasma-derived and serum-derived hsa-miR-193a-5p have been reported as promising indicators for diagnosing amyotrophic lateral sclerosis (ALS) ( 40 ), ovarian cancer ( 41 ), chronic myeloid leukemia ( 42 ), human T-cell leukemia virus type 1 (HTLV-1) infection ( 43 ), colorectal cancer metastasis ( 44 ), and aortic aneurysms ( 45 ). On the other hand, plasma-derived or serum-derived hsa-miR-551b-5p has been reported as a promising indicator of acute pancreatitis ( 46 , 47 ) and gastric cancer ( 48 ). As far as we are aware, there are no reports of using EV-derived miRNAs to diagnose MPM, and our report will be the first to do so.…”